Medical News

Benefit-Risk Profile of DAPT Continuation Beyond 1 Year afte...

Among patients with ESC-endorsed HTR who were free from major ischemic or bleeding events 1 year after coronary...

03 Jul 2020

Worst lead ST deviation and resolution of ST elevation at on...

WLR ST deviation one hour after PCI was a predictor of IS and MVO. WLR ST deviation, a measure easily obtained from...

02 Jul 2020

Impact of PRECISE-DAPT and DAPT Scores on Dual Antiplatelet...

Compared with short-duration DAPT, standard-duration DAPT was associated with similar net clinical outcomes and...

01 Jul 2020

Cardiovascular outcomes, bleeding risk, and achieved blood p...

Low achieved SBP associates with increased risk of death, SSE, and bleeding in patients with atrial fibrillation on...

30 Jun 2020

Key Trials

Identifying Atrial Fibrillation Patients using Smartwatch App Detected Pulse Irregularities

A smartwatch app may identify atrial fibrillation (AF) patients, based on an irregular pulse notification. Although the probability of receiving an...

Risk Stratification in PAH with a Comprehensive Echocardiographic Method

Integration of the echocardiographic parameters such as tricuspid annular plane systolic excursion (TAPSE), tricuspid regurgitation (TR) grade and...

GARFIELD-AF: Comparing the Outcomes for OAC vs. OAC plus Antiplatelet Therapy in Newly Diagnosed AF Patients

Atrial fibrillation (AF) patients who receive oral anticoagulants (OAC) should receive antiplatelet (AP) therapy only if clearly indicated for...

ISCHEMIA: Early Invasive vs. Conservative Strategy for Patients with Stable CAD

Optimized Medical Therapy (OMT) slows down the atherosclerotic disease, decreases future events of myocardial infarction, and longitudinally...

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

Email this page

Our Publications

Mexohar (Mexiletine) Monograph

About 5% of patients with cardiac arrhythmias or with heart failure are diagnosed with a ventricular tachycardia. Recurrent Ventricular Tachycardia...

Gutron (Midodrine hydrochloride) Monograph

Orthostatic Hypotension is common in elderly (>70 years of age) and can also occur secondary to neuropathy like in diabetes or central lesions...

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 


Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 


What percent of your patients who need oral anticoagulation, receive warfarin?
25% (5 votes)
20% (4 votes)
10% (2 votes)
15% (3 votes)
25% (5 votes)
Almost all
5% (1 vote)
Total votes: 20